Publicaciones en colaboración con investigadores/as de Universidad de Murcia (164)

2024

  1. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

  2. Identifying COPD patients with poor health status and low exercise tolerance through the five-repetition sit-to-stand test and modified Medical Research Council Dyspnea Score

    European Journal of Internal Medicine, Vol. 125, pp. 51-56

  3. Immune checkpoint inhibitors-associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

    Clinical and Translational Oncology

  4. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study

    European Journal of Heart Failure, Vol. 26, Núm. 4, pp. 776-784

  5. PICO questions and DELPHI methodology for improving the management of patients with acute hepatic porphyria

    Revista Clinica Espanola, Vol. 224, Núm. 5, pp. 272-280

  6. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  7. Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

    Cancers, Vol. 16, Núm. 14

  8. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  9. Relationship between academic climate and burnout in Spanish medical schools

    Educacion Medica, Vol. 25, Núm. 6

  10. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

  11. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

  12. Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)

    European Journal of Internal Medicine

  13. Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study

    The Lancet Haematology, Vol. 11, Núm. 8, pp. e606-e616

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. Academic climate and psychopathological symptomatology in Spanish medical students

    BMC Medical Education, Vol. 23, Núm. 1

  3. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  4. Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60 years

    GeroScience, Vol. 45, Núm. 1, pp. 543-553

  5. Analytical Tool for Quality Control of Irrigation Waters via a Potentiometric Electronic Tongue

    Chemosensors, Vol. 11, Núm. 7

  6. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  7. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031